Medtronic Inc. (NYSE: MDT) has announced the final follow-up results from its CoreValve® CE Pivotal Study, which looks to be good news for heart patients. In a press release, Medtronic said the CoreValve System demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who were treated with the self-expanding CoreValve System. …read more.